Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Glioblastoma 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Gliosarcoma 6Burkitt Lymphoma 6Astrocytoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Myeloproliferative Disorders 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Oligodendroglioma 4Medulloblastoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Carcinoma, Renal Cell 4Breast Neoplasms, Male 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 11X-Rays 8Biopsy 8Temozolomide 7Phantoms, Imaging 7Radiotherapy 6Nuclear Medicine Department, Hospital 6Bevacizumab 6erdafitinib 4Surgical Procedures, Operative 4Radiation 4Nivolumab 4Carmustine 4Carboplatin 4ulixertinib 3temsirolimus 3palbociclib 3olaparib 3larotrectinib 3Vorinostat 3Sunitinib 3IL13-PE38 3Chemotherapy, Adjuvant 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Glioma × Vorinostat × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01266031 2018-07-31

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
96 enrolled 15 charts
CNS

Glioblastoma, Glioma

NCT01378481 2014-12-23

High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma

National Cancer Institute (NCI)

Phase 1 Terminated
30 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡